C2N Diagnostics

C2N Diagnostics vision is to bring Clarity Through InnovationTM. It focuses its therapeutic discovery efforts around mechanism-based approaches to prevent or stop the progression of human neurological disorders. Diagnostic efforts revolve around bringing accurate, widely accessible, and cost-effective blood tests to the clinic for the betterment of patient care and brain health monitoring. Its lead commercial product, the PrecivityADTM blood test, is a mass spectrometry-based test performed in C2Ns CLIA-certified lab that measures in blood multiple analytes including A42, A40, and apolipoprotein E isoforms. While the test by itself cannot diagnose Alzheimers disease which is a clinical diagnosis made by a health care provider the test is an important new tool for physicians to aid in the evaluation process. PrecivityADTM, which can only be ordered through a health care provider, predicts brain amyloid plaques as determined by PET scan results and in 2019 it received a Breakthro...